Estradiol is the primary estrogen your ovaries produce during your reproductive years, and it’s the gold standard for hormone replacement therapy. When your provider prescribes estradiol for menopause, you’re receiving the bioidentical hormone — chemically identical to what your body made naturally.
But how that estradiol reaches your bloodstream matters more than most women realize. Luvo offers three systemic estradiol formulations — tablets, cream, and patches — and each has distinct absorption characteristics, clinical advantages, and lifestyle implications. Understanding these differences helps you and your Luvo provider choose the option that’s genuinely right for you.
Oral estradiol tablets are the most traditional form of systemic HRT. You swallow a tablet daily, and the estradiol is absorbed through the GI tract and processed by the liver before entering the general circulation.
This “first-pass” hepatic metabolism is the defining characteristic of oral estradiol. As the hormone passes through the liver, it triggers the production of various proteins including clotting factors and sex hormone-binding globulin (SHBG). This hepatic effect is clinically relevant — it’s the reason oral estrogen carries a slightly higher risk of venous thromboembolism (blood clots) compared to transdermal routes.
That said, oral estradiol remains safe and effective for many women, particularly those at low baseline risk for clotting events. The advantages include simplicity and familiarity (it’s just a pill), well-established dosing protocols with decades of clinical data, and effective relief of hot flashes, night sweats, and other systemic symptoms.
Luvo’s estradiol tablets are bioidentical estradiol — not the conjugated equine estrogens (Premarin) used in older studies. This distinction matters for both efficacy and safety.
Estradiol cream is applied to the skin — typically the inner arm, thigh, or abdomen — where it absorbs through the dermis directly into the bloodstream, bypassing the liver entirely.
This avoidance of first-pass metabolism is the primary clinical advantage of transdermal estradiol. Without hepatic processing, transdermal estradiol does not increase clotting factor production, making it a safer option for women with elevated thrombotic risk, including those with obesity, a history of migraines with aura, or moderate cardiovascular risk factors.
Estradiol cream offers flexibility in dosing because the amount applied can be adjusted more granularly than with fixed-dose tablets or patches. This can be advantageous during the early titration phase when finding the right dose.
The practical considerations include a brief daily application routine (1–2 minutes), a short drying period before dressing, and the need to avoid washing the application site for several hours. Some women prefer the sense of control that topical application provides.
Estradiol patches are adhesive patches applied to the skin, typically on the lower abdomen or hip, and replaced once or twice weekly depending on the formulation. Like cream, patches deliver estradiol transdermally, bypassing liver metabolism.
The standout advantage of patches is steady-state hormone delivery. While oral estradiol produces peaks and troughs as the tablet is absorbed and metabolized, patches release a consistent amount of estradiol around the clock. This steady delivery can result in fewer hormonal fluctuations and more consistent symptom control.
Patches share the safety advantages of all transdermal delivery — no increased clotting risk from hepatic stimulation. They’re also the most “set-and-forget” option, requiring attention only once or twice per week.
The trade-offs include potential skin irritation at the application site (rotating sites helps), adhesion issues in humid climates or with heavy sweating, and visibility (though patches can be placed in areas covered by clothing).
For women who want effective HRT with minimal daily routine and the safest thrombotic profile, patches are often the preferred choice.
Your Luvo provider will guide this decision based on clinical factors and your preferences, but here’s a general framework.
Choose tablets if you prefer the simplicity of a daily pill, have no elevated risk for blood clots, and want a well-established, familiar treatment format.
Choose cream if you have risk factors for thrombosis, prefer flexible dosing, want transdermal safety benefits, and don’t mind a brief daily application routine.
Choose patches if you want the most consistent hormone levels, prefer a twice-weekly routine over daily, want transdermal safety with maximum convenience, and don’t have skin sensitivity to adhesives.
Many women try one formulation and switch to another based on their experience — and Luvo’s program makes switching straightforward. The goal is finding the delivery method that integrates most naturally into your life while providing optimal symptom relief.
Visit Luvo’s hormone replacement program to discuss your options with a provider, or explore each formulation: estradiol tablets, estradiol cream, and estradiol patches.
If your understanding of hormone replacement therapy is shaped by headlines from 20 years ago, it’s time for an update. The 2002 Women’s Health Initiative (WHI) study sent shockwaves through medicine, leading millions of women to abandon HRT and a generation of physicians to stop prescribing it. But the decades since have brought dramatic clarity: the WHI’s findings were widely misinterpreted, and the resulting fear of HRT caused immeasurable harm to women who could have benefited from treatment.
Today, major medical organizations including the North American Menopause Society, the Endocrine Society, and the American College of Obstetricians and Gynecologists affirm that HRT is safe and effective for most women experiencing menopause symptoms, particularly when started within 10 years of menopause onset.
Luvo’s hormone replacement program is built on this modern evidence base. With 10 medication options spanning estradiol formulations, testosterone therapy, and non-hormonal alternatives, it offers a level of treatment personalization that most competitors simply can’t match.
Menopause isn’t a single event — it’s a transition that typically spans several years. The process begins in perimenopause, usually in the mid-40s, when the ovaries begin producing less estrogen and progesterone. Hormone levels fluctuate unpredictably, causing symptoms that can range from mildly annoying to severely disruptive.
Menopause is officially reached when 12 consecutive months pass without a menstrual period, typically around age 51. At this point, the ovaries have largely ceased producing estrogen, and levels of this hormone remain permanently low.
Estrogen isn’t just a reproductive hormone. It has receptors throughout the body — in the brain, bones, cardiovascular system, urogenital tract, skin, and joints. When estrogen declines, the effects cascade across multiple systems: vasomotor symptoms like hot flashes and night sweats, sleep disruption, mood changes and cognitive fog, vaginal dryness and urogenital atrophy, bone density loss, cardiovascular risk changes, joint pain and muscle loss, and skin and hair changes.
Testosterone also declines in women, though more gradually. By menopause, a woman’s testosterone level may be half what it was in her 20s, contributing to decreased libido, reduced energy, and loss of muscle mass.
HRT addresses these declines by restoring hormones to levels that alleviate symptoms and protect long-term health.
What sets Luvo apart from competitors like Hims, Willow, or Pomegranate is the breadth of our medication options. Managing hormonal decline isn’t one-size-fits-all, and neither is our program.
Estradiol is available in five formulations: oral tablets for systemic hormone delivery, transdermal cream for absorption through the skin, transdermal patches for steady-state hormone levels, vaginal gel for localized urogenital symptom relief, and vaginal tablets for targeted vaginal atrophy treatment.
Testosterone for women is available in three formulations: injection, oral tablets, and topical gel — addressing the often-overlooked role of testosterone in female vitality, libido, and body composition.
Non-hormonal options include Paroxetine, the only FDA-approved non-hormonal treatment for vasomotor symptoms, and Desvenlafaxine, an SNRI with strong evidence for hot flash reduction. These serve women who cannot or prefer not to use hormonal therapy.
This 10-medication toolkit means your Luvo provider can design a protocol precisely matched to your symptoms, health history, preferences, and risk profile.
HRT is most clearly indicated for women experiencing moderate to severe vasomotor symptoms such as hot flashes and night sweats, women under 60 or within 10 years of menopause onset (the “window of opportunity” for cardiovascular and bone benefits), women with premature ovarian insufficiency or early menopause (before age 40), women with significant urogenital symptoms like vaginal dryness, painful intercourse, or recurrent UTIs, and women at elevated risk for osteoporosis.
HRT may require additional evaluation or alternatives for women with a history of breast cancer, women with active cardiovascular disease or a history of blood clots, women with undiagnosed vaginal bleeding, and women with active liver disease.
Luvo’s providers conduct thorough health evaluations to determine the safest and most effective approach for each patient. For women who cannot use estrogen, our non-hormonal options provide meaningful symptom relief.
Explore Luvo’s full hormone replacement program to learn more.
No two women experience menopause the same way. Some are primarily bothered by hot flashes. Others struggle most with vaginal dryness or painful sex. Some are blindsided by mood changes and cognitive fog. And many deal with multiple symptoms simultaneously, each requiring its own treatment consideration.
The problem with one-size-fits-all HRT programs is that they treat menopause as a single condition with a single solution. Luvo’s program takes a symptom-specific approach, matching treatments to what you’re actually experiencing. This guide maps common menopause symptoms to the Luvo medications most effective for each.
Vasomotor symptoms are the hallmark of menopause, affecting up to 80% of women. They’re caused by estrogen-withdrawal-driven instability in the hypothalamic thermoregulatory center.
First-line treatments from Luvo include systemic estradiol, which directly addresses the underlying estrogen deficit. Estradiol tablets, cream, or patches all effectively reduce hot flash frequency and severity, typically by 75–95%. Transdermal options (cream and patches) are preferred for women with clotting risk factors.
For women who cannot take estrogen, Paroxetine is the FDA-approved non-hormonal option, reducing hot flash frequency by 33–65%. Desvenlafaxine offers potentially greater reduction at 55–70% and the added benefit of norepinephrine activity for energy and mood.
Night sweats are essentially nocturnal hot flashes and respond to the same treatments. Because they disrupt sleep, addressing them often produces cascading improvements in daytime energy, mood, and cognitive function.
Genitourinary syndrome of menopause (GSM) is progressive and affects the majority of postmenopausal women.
Localized vaginal estradiol is the most direct and effective treatment. Luvo’s estradiol vaginal gel and vaginal tablets deliver estrogen directly to the affected tissues with minimal systemic absorption. Most women experience significant improvement within 2–4 weeks, with continued improvement over 3 months.
Systemic estradiol (tablets, cream, or patches) provides some vaginal benefit as well, but many women with GSM need the additional concentrated local therapy that vaginal formulations provide.
For women who cannot use any form of estrogen, regular use of vaginal moisturizers and lubricants combined with Paroxetine or Desvenlafaxine for any accompanying vasomotor symptoms is the recommended alternative approach.
Declining sexual desire is one of the most distressing menopause symptoms and one of the most undertreated. It has both estrogen and testosterone components.
Testosterone therapy is the most evidence-based treatment for hypoactive sexual desire in postmenopausal women. Luvo’s testosterone injection, tablets, or gel can be added to an estradiol regimen (or used alone) to address libido directly. The 2019 Lancet meta-analysis confirmed that testosterone significantly improves desire, arousal, orgasm, and satisfaction in postmenopausal women.
Estradiol addresses the physical component by improving vaginal health, lubrication, and comfort during intercourse. When sex is no longer painful (thanks to vaginal estradiol), desire often improves as well.
The combination of systemic estradiol plus vaginal estradiol plus testosterone addresses sexual dysfunction from every angle — hormonal drive, physical comfort, and tissue health. This comprehensive approach is one of Luvo’s key differentiators.
Mood symptoms during menopause are driven by multiple factors: estrogen’s effects on serotonin and other neurotransmitters, sleep disruption from night sweats, and the psychological impact of the transition itself.
Estradiol therapy often produces significant mood improvement, particularly when mood symptoms are clearly linked to the menopausal transition. Stabilizing estrogen levels helps stabilize the neurochemical environment.
Paroxetine and Desvenlafaxine address mood symptoms through direct serotonergic and noradrenergic mechanisms. For women whose mood symptoms are severe, these medications may be used alongside or instead of estradiol. Desvenlafaxine’s SNRI mechanism may be particularly effective for the combination of depression, fatigue, and hot flashes.
Testosterone can contribute to improved mood, confidence, and overall sense of well-being. It’s rarely used as a primary mood treatment but can provide meaningful benefit as part of a comprehensive protocol.
Cognitive changes, persistent fatigue, and loss of lean mass are increasingly recognized as significant menopause symptoms driven by both estrogen and testosterone decline.
Estradiol supports cognitive function through its effects on cerebral blood flow, synaptic plasticity, and neurotransmitter function. Many women report improved mental clarity within weeks of starting estradiol therapy.
Testosterone’s role in energy, cognitive sharpness, and muscle maintenance makes it a valuable addition for women experiencing these symptoms. The anabolic effects of testosterone help maintain the lean mass and metabolic rate that decline during menopause.
Desvenlafaxine’s norepinephrine activity can address fatigue and cognitive fog independently of hormonal mechanisms, making it useful either as a complement to HRT or as a standalone option.
Luvo’s program recognizes that these symptoms often require a multi-medication strategy. Your provider will build a protocol that addresses your complete symptom picture. Visit the hormone replacement program to get started.
The Women’s Health Initiative (WHI) study, published in 2002, is the most influential — and most misunderstood — study in the history of hormone replacement therapy. Its initial results, which were widely reported as showing that HRT causes breast cancer and heart disease, led to millions of women abruptly stopping treatment and a generation of providers becoming afraid to prescribe it.
The human cost of this overreaction has been enormous. Women suffered through severe menopause symptoms unnecessarily. Rates of osteoporotic fractures increased. The gap between what the evidence actually shows and what many women (and some providers) believe about HRT remains one of the biggest failures of medical communication in modern history.
This article provides a clear, evidence-based assessment of what we actually know about HRT safety in 2026.
The WHI studied two specific regimens: oral conjugated equine estrogens (Premarin) plus medroxyprogesterone acetate (Provera) in women with a uterus, and Premarin alone in women who’d had a hysterectomy.
The estrogen-only arm actually showed a decreased risk of breast cancer and no increased cardiovascular risk. It was stopped early simply because it was part of the same administrative trial as the combination arm.
The combination arm showed a small increased risk of breast cancer (8 additional cases per 10,000 women per year) and a small increased risk of cardiovascular events. However, these risks were concentrated in women who started HRT more than 10 years after menopause and were over age 60 — a population very different from the typical woman who begins HRT in her early 50s.
Critically, the WHI used oral conjugated equine estrogens (derived from horse urine, containing multiple estrogen compounds) and a synthetic progestin (medroxyprogesterone acetate) — not the bioidentical estradiol and micronized progesterone that modern HRT typically uses. Subsequent research has shown that bioidentical formulations and transdermal delivery have substantially different risk profiles.
Breast cancer risk with modern HRT is more nuanced than headlines suggest. Estrogen-only therapy does not increase breast cancer risk and may reduce it. The combination of estrogen plus micronized progesterone (the bioidentical progestogen) appears to carry less breast cancer risk than the synthetic progestins used in the WHI. When risk does exist, it’s small in absolute terms and similar to risks associated with common lifestyle factors like alcohol consumption, obesity, and sedentary behavior.
Cardiovascular risk depends heavily on timing. The “timing hypothesis” is now well-established: women who start HRT within 10 years of menopause or before age 60 show neutral or even beneficial cardiovascular effects. Women who start HRT later may face increased risk. This window of opportunity is a key consideration in Luvo’s prescribing approach.
Venous thromboembolism (blood clot) risk is increased with oral estrogen but not with transdermal estrogen. This is one of the most clinically actionable findings in modern HRT research — and it’s why Luvo offers transdermal options (cream and patches) alongside tablets.
Stroke risk shows a similar pattern to clotting risk: modestly increased with oral estrogen, not increased with transdermal delivery, and dose-dependent. Using the lowest effective dose and transdermal delivery minimizes this concern.
Luvo’s hormone replacement program is designed with risk minimization built into every level.
Formulation selection matters. Luvo uses bioidentical estradiol, not conjugated equine estrogens. The availability of transdermal options (cream and patches) allows women with clotting risk factors to avoid oral estrogen entirely.
Route-of-delivery matching means your provider recommends the delivery method based on your risk profile, not just convenience. Women with elevated thrombotic risk are guided toward transdermal options. Women with predominantly vaginal symptoms may use localized therapy with minimal systemic exposure.
Non-hormonal alternatives ensure that women who cannot safely use estrogen still have effective treatment options. Paroxetine and Desvenlafaxine provide meaningful relief without any hormonal exposure.
Timing considerations are respected. Luvo’s providers follow the evidence-based window of opportunity, recommending HRT initiation for appropriate candidates within 10 years of menopause onset.
Ongoing monitoring through regular follow-ups ensures that treatment remains appropriate and effective over time, with dose adjustments as needed.
This comprehensive, evidence-informed approach to risk management is what distinguishes Luvo from competitors that offer a limited menu of options with minimal clinical nuance. Explore the full hormone replacement program.